Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Bioavailability of Nalbuphine ER in Healthy Subjects
NCT07487740Phase 1Completed
- Sponsor
- Trevi Therapeutics
- Start
- Feb 2026
- Primary completion
- May 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nalbuphine in pruritus and chronic cough (2 cohorts), sponsored by Trevi Therapeutics. Primary endpoint: Relative Bioavailability. Started Feb 2026; status: completed.
02
Drugs
nalbuphine
03
Conditions
prurituschronic cough
Beyond the preview
Go deeper on NCT07487740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07487740.